Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Dalcinonacog alfa in Hemophilia B
NCT03995784Phase 2Completed
- Sponsor
- Gyre Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dalcinonacog alfa in hemophilia B (HB), sponsored by Gyre Therapeutics, Inc.. Started Jun 2019; status: completed.
02
Drugs
dalcinonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03995784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995784.